Merck said its anti-TL1A monoclonal antibody tulisokibart (MK-7240) met both primary and key secondary endpoints in a Phase II hidradenitis suppurativa study, but missed the primary endpoint in a separate Phase II trial in systemic sclerosis-associated interstitial lung disease. The mixed readout, disclosed alongside second-quarter results, keeps momentum alive in dermatology while halting development in SSc-ILD, a Disorder of lung.

Why It Matters To Oncology

• For oncology clinicians tracking drug discovery, the update is a reminder that large-cap cancer players are increasingly leaning on immunology assets to diversify ahead of major patent cliffs, including Keytruda.

• Tulisokibart came through Merck’s $10.8 billion Prometheus acquisition and is part of a broader bet on TL1A biology, a pathway being explored for immune-mediated inflammation and fibrosis.

• Even outside cancer, the readout matters because platform confidence, safety, and combination potential can shape how companies allocate R&D capital across therapeutic areas.

The Financials

• Merck disclosed the data alongside its Q2 earnings report as it looks for future growth drivers ahead of pembrolizumab patent expiry.

• The company acquired Prometheus Biosciences for $10.8 billion, making tulisokibart a high-profile pipeline asset with material strategic importance.

• Positive HS and ulcerative colitis signals may help support the asset’s value, even as the SSc-ILD miss narrows its near-term expansion path.

What They're Saying

• Dean Li, president of Merck Research Laboratories, called SSc-ILD a “challenging and refractory disease” and said, “I don't know any anti-cytokine that has worked” there.

• Li said the HS data give Merck “more confidence in the derm possibilities for this drug.”

• He also emphasized the “extremely clean” safety profile, arguing that could enable indication-specific combination strategies across inflammatory diseases.

What's Next

• Merck will halt development of tulisokibart in SSc-ILD after the Phase II miss.

• The company continues a broad mid-stage program in axial spondyloarthritis, psoriatic arthritis, rheumatoid arthritis, and systemic sclerosis.

• Phase III programs are ongoing in inflammatory bowel disease, including Crohn’s disease and ulcerative colitis; Merck said in June that tulisokibart met the primary endpoint in a Phase III UC trial.